PDF herunterladen
Thromb Haemost 1985; 54(03): 630-634
DOI: 10.1055/s-0038-1660086
Original Article
Schattauer GmbH Stuttgart

The Measurement of Heparin and Other Therapeutic Sufphated Polysaccharides in Plasma, Serum and Urine

J Dawes
1   The MRC/SNBTS Blood Components Assay Group, Edinburgh, UK
,
C V Prowse
2   The Edinburgh & S-E Scotland Blood Transfusion Service, Edinburgh, UK
,
D D Pepper
3   The SNBTS Headquarters Laboratory, Edinburgh, UK
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 30. April 1985

Accepted 29. Juli 1985

Publikationsdatum:
19. Juli 2018 (online)

Auch verfügbar auf
  als PDF herunterladen  Lizenzen und Reprints

Summary

The competitive binding assay described will specifically and accurately measure concentrations of administered heparin in biological fluids with a sensitivity of 60 ng ml-1. Neither endogenous glycosaminoglycans, nor plasma proteins such as ATIII and PF4 interfere in the assay. Semi-synthetic highly sulphated heparinoids and LMW heparin can also be measured. Using this assay heparin clearance followed simple first-order kinetics over the dose range 100-5,000 units, but the half-life was strongly dose-dependent. There was good correlation with heparin activity measurements by APTT and anti-Xa clotting assays. Plasma concentrations were measurable for at least 5 h following subcutaneous injection of 10,000 units of heparin. Excretion in the urine could be followed after all but the lowest intravenous dose. This assay, used in conjunction with measurements of heparin anticoagulant activity, will be valuable in the elucidation of mechanisms of action of heparin and the heparinoids, and in the assessment and management of problems related to heparin therapy.

Keywords

Heparin - Heparinoids - Competitive binding assay - Clearance - Volunteer studies
 

  • References

  • 1 Lee RI, White PD. A clinical study of the coagulation time of blood. Am J Med Sci 1913; 145: 495-503
    CrossrefPubMedGoogle Scholar
  • 2 Thomson JM. A Practical Guide to Blood Coagulation and Haemostasis. Churchill, London 1970; 1-369
    PubMedGoogle Scholar
  • 3 Andersson LO, Barrowcliffe TW, Homer E, Johnson EA, Sims GE C. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin III and by gel filtration. Thromb Res 1976; 9: 575-583
    CrossrefPubMedGoogle Scholar
  • 4 Eika C, Godal HC, Kierulf P. Detection of small amounts of heparin by the thrombin clotting time. Lancet 1972; 2: 376
    PubMedGoogle Scholar
  • 5 Yin ET, Wessler S, Butler JV. Plasma heparin: a unique, practical, submicrogram-sensitive assay. J Lab Clin Med 1973; 81: 298-310
    PubMedGoogle Scholar
  • 6 Teien AN, Lie M, Abilgaard U. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res 1976; 8: 413-416
    CrossrefPubMedGoogle Scholar
  • 7 Godal HC. Heparin assay methods for control of in vivo heparin effect. Thrombes Diathes Haemorrh 1975; 33: 77-80
    PubMedGoogle Scholar
  • 8 Teien AN, Lie M. Heparin assay in plasma: a comparison of five clotting methods. Thromb Res 1975; 7: 777-788
    CrossrefPubMedGoogle Scholar
  • 9 Lane DA, Michalski R, van Ross ME, Kakkar VV. Comparison of heparin and a semisynthetic heparin analogue, A 73025. Br J Haematol 1977; 37: 239-245
    CrossrefPubMedGoogle Scholar
  • 10 Fischer AM, Barrowcliffe TW, Thomas DP. A comparison of pentosan polysulphate (SP54) and heparin. I: mechanism of action on blood coagulation. Thromb Haemostas 1982; 47: 104-108
    PubMedGoogle Scholar
  • 11 Torngren S, Noren I, Forsskahl B, Sipila H. Effects of heparin and a semisynthetic heparin analogue on platelet aggregation, lipoprotein lipase and other laboratory tests in surgical patients. Thromb Res 1983; 30: 527-34
    CrossrefPubMedGoogle Scholar
  • 12 Thomas DP, Morton RE. A low molecular weight heparin compared with unfractionated heparin. Thromb Res 1982; 28: 343-350
    CrossrefPubMedGoogle Scholar
  • 13 Dawes J, Pepper DS. A sensitive competitive binding assay for exogenous and endogenous heparins. Thromb Res 1982; 27: 387-396
    CrossrefPubMedGoogle Scholar
  • 14 Dawes J, Pepper DS. Catabolism of low-dose heparin in man. Thromb Res 1979; 14: 845-860
    CrossrefPubMedGoogle Scholar
  • 15 Greenwood FC, Hunter WM, Glover JS. The preparation of 131I-labelled human growth hormone of high specific radio activity. Biochem J 1963; 89: 114-123
    CrossrefPubMedGoogle Scholar
  • 16 Hunter WM. Simplified solid-phase radioimmunoassay without centrifugation. Acta Endocrinol 1977; 85 Suppl (Suppl. 212) 463
    PubMedGoogle Scholar
  • 17 Dawes J, Smith RC, Pepper DS. The release, distribution and clearance of human β-thromboglobulin and platelet factor 4. Thromb Res 1978; 12: 851-861
    CrossrefPubMedGoogle Scholar
  • 18 Levy SW, Jaques LB. Appearance of heparin antithrombin-active chains in vivo after injection of commercial heparin and in anaphylaxis. Thromb Res 1978; 13: 429-441
    CrossrefPubMedGoogle Scholar
  • 19 Gundry SR, Klein MD, Drongowski RA, Kirsh MM. Clinical evaluation of a new rapid heparin assay using the dye azure A. Am J Surg 1984; 148: 191-194
    CrossrefPubMedGoogle Scholar
  • 20 Johnson EA, Mulloy B. Simple metachromatic assay methods for heparin and protamine. J Pharm Pharmacol 1976; 28: 836-837
    CrossrefPubMedGoogle Scholar
  • 21 Godal HC. A comparison of two heparin-neutralising agents, protamine and polybrene. Scand J Clin Lab Invest 1960; 12: 446-457
    CrossrefPubMedGoogle Scholar
  • 22 Calatroni A, Donnelly PV, di Ferrante N. The glycosaminoglycans of human plasma. J Clin Invest 1969; 48: 332-343
    CrossrefPubMedGoogle Scholar
  • 23 Varadi DP, Cifonelli JA, Dorman A. The acid mucopolysaccharides in normal urine. Biochim Biophys Acta 1967; 141: 103-117
    CrossrefPubMedGoogle Scholar
  • 24 Estes JW, Poulin PF. Pharmacokinetics of heparin. Clin Pharmacokinetics 1980; 5: 204-220
    CrossrefPubMedGoogle Scholar
  • 25 Estes JW, Poulin PF. Pharmacokinetics of heparin. Distribution and elimination. Thrombos Diathes Haemorrh 1974; 33: 26-37
    PubMedGoogle Scholar
  • 26 Levine SP, Sorenson RR, Harris MA, Knieriem LK. The effect of platelet factor 4 (PF4) on assays of plasma heparin. Br J Haematol 1984; 57: 585-596
    CrossrefPubMedGoogle Scholar
  • 27 Kraemer PM. Heparin releases heparan sulphate from the cell surface. Biochem Biophys Res Comm 1977; 78: 1334-1340
    CrossrefPubMedGoogle Scholar
  • 28 Cade JF, Buchanan MR, Boneu B, Ockleford P, Carter CJ, Cerskus AL, Hirsh J. A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: the influence of the method of preparation. Thromb Res 1984; 35: 613-625
    CrossrefPubMedGoogle Scholar
  • 29 MacGregor IR, Dawes J, Pepper DS, Prowse CV, Stocks J. Metabolism of sodium pentosan polysulphate in man measured by a new competitive binding assay for sulphated polysaccharides - comparison with effects upon anticoagulant activity, lipolysis and platelet α-granule proteins. Thromb Haemostas 1985; 53: 411-414
    PubMedGoogle Scholar
  • 30 Simon TL, Hyers TM, Gaston JP, Harker LA. Heparin pharmacokinetics: increased requirements in pulmonary embolism. Br J Haematol 1978; 39: 111-120
    CrossrefPubMedGoogle Scholar
  • 31 de Swart CAM, Nijkeyer B, Roelofs J MM, Sixma JJ. Kinetics of intravenously administered heparin in normal humans. Blood 1982; 60: 1251-1258
    PubMedGoogle Scholar
  • 32 Estes JW, Pelikan EW, Kruger-Thiemere K-T. A retrospective study of the pharmacokinetics of heparin. Clin Pharmacol Ther 1969; 10: 329-337
    CrossrefPubMedGoogle Scholar
  • 33 Barrowcliffe TW, Johnson EA, Eggleton CA, Thomas DP. Anticoagulant activities of lung and mucous heparins. Thromb Res 1977; 12: 27-36
    PubMedGoogle Scholar
  • 34 Thomas DP, Barrowcliffe TW, Merton RE, Stocks J, Dawes J, Pepper DS. In vivo release of anti-Xa clotting activity by a heparin analogue. Thromb Res 1980; 17: 831-840
    CrossrefPubMedGoogle Scholar
  • 35 Thomas DP. Heparin, low molecular weight heparin, and heparan analogues. Br J Haematol 1984; 58: 385-390
    CrossrefPubMedGoogle Scholar